Abstracts tagged "monoclonal antibodies and rheumatoid arthritis (RA)"

Abstract Number: 1935 • 2018 ACR/ARHP Annual Meeting
Multiple Dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP5094, an Anti-Alpha9 Integrin Monoclonal Antibody, in Patients with Rheumatoid Arthritis on Methotrexate
Jiayin Huang¹, Tomasz Wojtkowski¹, Paul Blahunka¹, Ronald Smulders² and Christopher Lademacher¹, ¹Astellas Pharma US, Inc., Northbrook, IL, ²Astellas Pharma Europe BV, Leiden, Netherlands
Background/Purpose: Joint synovium is the main tissue involved in rheumatoid arthritis (RA) lesions. Alpha9 integrin is expressed by synovial tissue lining cells and has been…
Abstract Number: 1907 • 2017 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics, and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study on Rheumatoid Arthritis: 52-Week Results
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisanori Umehara³, Toshihiro Nanki⁴, Nobuyuki Yasuda⁵, Fumitoshi Tago⁶, Makoto Kawakubo⁶, Yasumi Kitahara⁶, Seiichiro Hojo⁶, Tetsu Kawano⁷ and Toshio Imai⁷, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Division of Rheumatology and Immunology, Nagahama City Hospital, Shiga, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ⁵KAN Research Institute, Inc., Tokyo, Japan, ⁶Eisai Co., Ltd., Tokyo, Japan, ⁷KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: Fractalkine (CX3CL1/FKN) is a chemokine that regulates chemotaxis and adhesion of CX3C chemokine receptor 1 (CX3CR1)-expressing inflammatory cells. We previously presented the interim results…
Abstract Number: 1588 • 2016 ACR/ARHP Annual Meeting
Treatment with BI 655064 (Antagonistic Anti-CD40 Antibody) Modulates Clinical and Biomarker Parameters Associated with Rheumatoid Arthritis (RA)
Sudha Visvanathan¹, Meera Ramanujam¹, Corinna Schoelch², Patrick Baum², Richard Vinisko¹, Ralf Thiedmann², Ulf Müller-Ladner³, Stefan Daniluk⁴, Rafal Ptaszyński⁵, Steven Padula⁶, Jay S. Fine¹ and Jürgen Steffgen², ¹Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ²Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ³Giessen University, Kerckhoff-Klinik, Bad-Nauheim, Germany, ⁴ClinicMed Badurski and Partners, Bialystok, Poland, ⁵Rheumatica, Warsaw, Poland, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
Background/Purpose: Costimulation through the CD40–CD40L axis is implicated in the pathogenesis of RA including T cell-mediated responses, B cell-driven autoantibodies, adhesion molecule expression, synovial hyperplasia…
Abstract Number: 1632 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Sarilumab in Subgroups of Patients with Rheumatoid Arthritis from 2 Phase 3 Studies
Mark C. Genovese¹, Roy Fleischmann², Erin Mangan³, Janet van Adelsberg⁴, Melitza Iglesias-Rodriguez⁵, Deborah Dukovic⁶, Chunpeng Fan⁷ and Tom WJ Huizinga⁸, ¹Stanford University Medical Center, Palo Alto, CA, ²Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Clinical Science, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Sanofi Genzyme, Cambridge, MA, ⁶Sanofi Genzyme, Bridgewater, NJ, ⁷Biostatistics, Sanofi Genzyme, Bridgewater, NJ, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. Efficacy of sarilumab + MTX was demonstrated in patients with RA and inadequate response to MTX…
Abstract Number: 1633 • 2016 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcomes after 3 Years of Sarilumab in Patients with Rheumatoid Arthritis
Désirée van der Heijde¹, Janet van Adelsberg², Hubert van Hoogstraten³, Melitza Iglesias-Rodriguez⁴, Erin Mangan⁵, Neil Graham⁵, Deborah Dukovic³, Alberto Spindler⁶ and Mark C. Genovese⁷, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Clinical Science, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Sanofi Genzyme, Cambridge, MA, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Rheumatology, Universidad Nacional Tucumán, Yerba Buena Tucuman, Argentina, ⁷Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Sarilumab is a human mAb blocking the IL-6Rα. Sarilumab + MTX demonstrated significant improvements in RA signs and symptoms, physical function, and inhibition of…
Abstract Number: 13L • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy of E6011, an Anti-Fractalkine Monoclonal Antibody, in a First-in-Patient Phase 1/2 Study in Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisanori Umehara³, Toshihiro Nanki⁴, Hideto Akama⁵, Nobuyuki Yasuda⁵, Fumitoshi Tago⁵, Makoto Kawakubo⁵, Seiichiro Hojo⁵, Tetsu Kawano⁶ and Toshio Imai⁶, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Dept. of Internal Medicine, School of Medicine Keio University, Tokyo, Japan, ³Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁵EISAI Co. Ltd., Tokyo, Japan, ⁶KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C-chemokine which leads to dual actions, chemotaxis and cell adhesion for leukocytes…
Abstract Number: 2874 • 2014 ACR/ARHP Annual Meeting
Pro-Inflammatory FcRL4+ Memory B Cells in Joints of RA Patients: Immunoglobulin Gene Characteristics and Antigen Specificity
Khaled Amara¹, Lorraine Yeo², Natalie Sippl¹, Philip Titcombe¹, Andrew Filer³, Karim Raza³, Dagmar Scheel-Toellner² and Vivianne Malmström⁴, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, SE-17176 Solna, Stockholm, Sweden., Stockholm, Sweden, ²Rheumatology Research Group, Centre for Translational Inflammation Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK, Birmingham, United Kingdom, ³Rheumatology Research Group, MRC Centre for Immune Regulation, School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ⁴Medicine, Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Our recent findings identified a subset of pro-inflammatory memory B cells in the RA synovium characterized by the expression of the surface protein…
Abstract Number: 2647 • 2013 ACR/ARHP Annual Meeting
Recombinant Monoclonal Antibodies Derived From Single CD19+ Synovial B Cells Of RA Patients With Tertiary Lymphoid Structures Display a Strong Immunoreactivity Towards Citrullinated Histones
Elisa Corsiero¹, Michele Bombardieri², Emanuela Carlotti¹, Hedda Wardemann³, William H. Robinson⁴ and Costantino Pitzalis¹, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, QMUL, London, United Kingdom, ²Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ³Max Planck Research Group Molecular Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, ⁴Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Rheumatoid arthritis (RA) is characterised by breach of self-tolerance towards citrullinated proteins. Around 40% of patients display synovial tertiary lymphoid structures (TLS) with functional…
Abstract Number: 2578 • 2012 ACR/ARHP Annual Meeting
Monoclonal IgG Antibodies (ACPAs) From Synovial Fluid B Cells of Rheumatoid Arthritis Patients – Antigen-Driven Affinity Maturation and Cross Reactivity
Khaled Amara¹, Johanna Steen², Fiona Murray², Henner Morbach³, Blanca Fernandez-Rodriguez⁴, Vijay Balasingh², Marianne Engström², Omri Snir², Lena Israelsson⁵, Anca Catrina², Hedda Wardemann⁶, Davide Corti⁴, Eric Meffre Sr.³, Lars Klareskog⁷ and Vivianne Malmström⁸, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, SE-17176 Solna, Stockholm, Sweden., Stockholm, Sweden, ²Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Department of Immunobiology, Yale University School of Medicine, New Haven, CT, ⁴Institute for Research in Biomedicine, Bellinzona, Switzerland, ⁵Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁶Max Planck Research Group Molecular Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, ⁷Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Antibodies targeting citrullinated proteins (ACPA) are commonly found in patients with Rheumatoid Arthritis (RA), strongly associate with distinct HLA-DR alleles and predict a more…
Abstract Number: 1320 • 2012 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Mark C. Genovese¹, Roy Fleischmann², Martine Jasson³, Allen R. Radin⁴, Jennifer Hamilton⁵ and Tom W.J. Huizinga⁶, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ³Clinical Development, Sanofi-Aventis, Paris, France, ⁴Translational Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁵Predictive Medicine, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anemia of chronic disease, a common extra-articular manifestation of rheumatoid arthritis (RA), which has a substantial impact on patient function, is driven in part…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].